A blueprint for academic laboratories to produce SARS-CoV-2 quantitative RT-PCR test kits
© 2020 Mascuch et al..
Widespread testing for the presence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals remains vital for controlling the COVID-19 pandemic prior to the advent of an effective treatment. Challenges in testing can be traced to an initial shortage of supplies, expertise, and/or instrumentation necessary to detect the virus by quantitative RT-PCR (RT-qPCR), the most robust, sensitive, and specific assay currently available. Here we show that academic biochemistry and molecular biology laboratories equipped with appropriate expertise and infrastructure can replicate commercially available SARS-CoV-2 RT-qPCR test kits and backfill pipeline shortages. The Georgia Tech COVID-19 Test Kit Support Group, composed of faculty, staff, and trainees across the biotechnology quad at Georgia Institute of Technology, synthesized multiplexed primers and probes and formulated a master mix composed of enzymes and proteins produced in-house. Our in-house kit compares favorably with a commercial product used for diagnostic testing. We also developed an environmental testing protocol to readily monitor surfaces for the presence of SARS-CoV-2. Our blueprint should be readily reproducible by research teams at other institutions, and our protocols may be modified and adapted to enable SARS-CoV-2 detection in more resource-limited settings.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:295 |
|---|---|
| Enthalten in: |
The Journal of biological chemistry - 295(2020), 46 vom: 13. Nov., Seite 15438-15453 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.12.2020 Date Revised 16.02.2024 published: Print-Electronic UpdateOf: medRxiv. 2020 Jul 31;:. - PMID 32766604 Citation Status MEDLINE |
|---|
| doi: |
10.1074/jbc.RA120.015434 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314566538 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314566538 | ||
| 003 | DE-627 | ||
| 005 | 20240216232100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1074/jbc.RA120.015434 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM314566538 | ||
| 035 | |a (NLM)32883809 | ||
| 035 | |a (PII)S0021-9258(17)50379-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mascuch, Samantha J |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A blueprint for academic laboratories to produce SARS-CoV-2 quantitative RT-PCR test kits |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2020 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2020 Jul 31;:. - PMID 32766604 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Mascuch et al. | ||
| 520 | |a Widespread testing for the presence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals remains vital for controlling the COVID-19 pandemic prior to the advent of an effective treatment. Challenges in testing can be traced to an initial shortage of supplies, expertise, and/or instrumentation necessary to detect the virus by quantitative RT-PCR (RT-qPCR), the most robust, sensitive, and specific assay currently available. Here we show that academic biochemistry and molecular biology laboratories equipped with appropriate expertise and infrastructure can replicate commercially available SARS-CoV-2 RT-qPCR test kits and backfill pipeline shortages. The Georgia Tech COVID-19 Test Kit Support Group, composed of faculty, staff, and trainees across the biotechnology quad at Georgia Institute of Technology, synthesized multiplexed primers and probes and formulated a master mix composed of enzymes and proteins produced in-house. Our in-house kit compares favorably with a commercial product used for diagnostic testing. We also developed an environmental testing protocol to readily monitor surfaces for the presence of SARS-CoV-2. Our blueprint should be readily reproducible by research teams at other institutions, and our protocols may be modified and adapted to enable SARS-CoV-2 detection in more resource-limited settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a DNA polymerase | |
| 650 | 4 | |a RNA | |
| 650 | 4 | |a RT-qPCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a formulation | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a polymerase chain reaction (PCR) | |
| 650 | 4 | |a protein purification | |
| 650 | 4 | |a reverse transcriptase | |
| 650 | 4 | |a reverse transcription | |
| 650 | 4 | |a ribonuclease inhibitor | |
| 650 | 4 | |a virus | |
| 650 | 7 | |a Reagent Kits, Diagnostic |2 NLM | |
| 700 | 1 | |a Fakhretaha-Aval, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Bowman, Jessica C |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Minh Thu H |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Gwendell |e verfasserin |4 aut | |
| 700 | 1 | |a Bommarius, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Chieri |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Liangjun |e verfasserin |4 aut | |
| 700 | 1 | |a Newnam, Gary P |e verfasserin |4 aut | |
| 700 | 1 | |a Matange, Kavita R |e verfasserin |4 aut | |
| 700 | 1 | |a Thapa, Hem R |e verfasserin |4 aut | |
| 700 | 1 | |a Barlow, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Donegan, Rebecca K |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Nguyet A |e verfasserin |4 aut | |
| 700 | 1 | |a Saccuzzo, Emily G |e verfasserin |4 aut | |
| 700 | 1 | |a Obianyor, Chiamaka T |e verfasserin |4 aut | |
| 700 | 1 | |a Karunakaran, Suneesh C |e verfasserin |4 aut | |
| 700 | 1 | |a Pollet, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Rothschild-Mancinelli, Brooke |e verfasserin |4 aut | |
| 700 | 1 | |a Mestre-Fos, Santi |e verfasserin |4 aut | |
| 700 | 1 | |a Guth-Metzler, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Bryksin, Anton V |e verfasserin |4 aut | |
| 700 | 1 | |a Petrov, Anton S |e verfasserin |4 aut | |
| 700 | 1 | |a Hazell, Mallory |e verfasserin |4 aut | |
| 700 | 1 | |a Ibberson, Carolyn B |e verfasserin |4 aut | |
| 700 | 1 | |a Penev, Petar I |e verfasserin |4 aut | |
| 700 | 1 | |a Mannino, Robert G |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Wilbur A |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Andrés J |e verfasserin |4 aut | |
| 700 | 1 | |a Kubanek, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Vinayak |e verfasserin |4 aut | |
| 700 | 1 | |a Hud, Nicholas V |e verfasserin |4 aut | |
| 700 | 1 | |a Glass, Jennifer B |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Loren Dean |e verfasserin |4 aut | |
| 700 | 1 | |a Lieberman, Raquel L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of biological chemistry |d 1945 |g 295(2020), 46 vom: 13. Nov., Seite 15438-15453 |w (DE-627)NLM000004995 |x 1083-351X |7 nnns |
| 773 | 1 | 8 | |g volume:295 |g year:2020 |g number:46 |g day:13 |g month:11 |g pages:15438-15453 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1074/jbc.RA120.015434 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 295 |j 2020 |e 46 |b 13 |c 11 |h 15438-15453 | ||